Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells $91,500.00 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 150,000 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00. Following the transaction, the director now owns 4,538,079 shares of the company’s stock, valued at $2,768,228.19. This represents a 3.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.

Invivyd Price Performance

Shares of IVVD opened at $0.55 on Friday. The firm’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.07. The company has a market capitalization of $65.43 million, a P/E ratio of -0.28 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.54 and a 1-year high of $5.20.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the stock. Proficio Capital Partners LLC purchased a new stake in Invivyd in the third quarter valued at approximately $27,000. SG Americas Securities LLC grew its holdings in shares of Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after purchasing an additional 25,201 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. bought a new position in shares of Invivyd in the second quarter worth approximately $86,000. Finally, Rhumbline Advisers grew its holdings in shares of Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IVVD. Morgan Stanley lowered their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. HC Wainwright lowered their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.